Genting Berhad Sponsored ADR (GEBHY) – Globe Newswire
-
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
-
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
-
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
-
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
-
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
-
Codex DNA Expands Application of Proprietary Error Correction Technology
-
Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands
-
Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation
-
Codex DNA Reports Second Quarter 2022 Financial Results
-
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
-
Codex DNA to Present at the 2022 Jefferies Healthcare Conference
-
Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference
-
Codex DNA Reports First Quarter 2022 Financial Results
-
Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
-
Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo
-
Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA
-
Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022
-
Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference
-
Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance
-
Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022
-
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
-
Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference
-
Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
-
Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics
-
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Developm
-
Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant
-
Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System
-
Codex DNA to Present at the Jefferies London Healthcare Conference
-
Codex DNA Reports Third Quarter 2021 Financial Results
-
Codex DNA Acquires Eton Bioscience
-
Codex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
-
Codex DNA Reports Second Quarter 2021 Financial Results
-
Codex DNA Announces Synthetic Biology Collaboration with U.S. Department of Agriculture to Combat Citrus Greening Disease
-
Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
-
Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology
-
Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Back to GEBHY Stock Lookup
